Showing 1 - 5 of 5
Potential Impact of Takeda’s Dengue Vaccine Candidate Reinforced by Long-Term Safety and Efficacy Results
Published on 24/05/2021
» •Takeda’s dengue vaccine candidate (TAK-003) prevented 83.6% of hospitalizations and 62.0% of dengue illness overall, with no identified important safety risks through three years following vaccination in ongoing pivotal Phase 3 TIDES trial • Regulatory filings for TAK-003 progressing in European Union and in many dengue-endemic countries; filing in United States planned for later this year • Dengue is the fastest-spreading mosquito-borne viral disease with an estimated 390 million cases and 500,000 hospitalizations per year globally, with limited options for prevention
What makes DaReal Media the #1 Agency for Content Creators & Celebrities
Published on 21/05/2021
» The digital realm has become increasingly important over the years. Marketing online has become essential to achieve powerful growth for any brand or business.
Takeda begins regulatory submissions for dengue vaccine candidate in the EU, Latin America, South America, South Asia and ASEAN
Published on 28/04/2021
» Takeda Pharmaceutical Company, a leading global biopharmaceutical with headquarters in Japan, announced that the European Medicines Agency (EMA) has accepted the Company’s filing packages for its dengue vaccine candidate (TAK-003), which is being investigated in the Phase 3 trial for the efficacy and safety in prevention of dengue due to any dengue virus serotypes in individuals aged 4–60 years.
Takeda Begins Regulatory Submissions for Dengue Vaccine Candidate in EU and Dengue-Endemic Countries
Published on 30/03/2021
» Takeda Begins Regulatory Submissions for Dengue Vaccine Candidate in EU and Dengue-Endemic Countries
The inspirational tale of Manny Garcia's entrepreneurial journey
Published on 12/02/2021
» When you’re desperate for cash, it’s easy to cut corners, compromise your values, and deliver an inferior product or service. A businessman who can focus on the ability to live up to his visions from start to finish is the one that will thrive longest and shine brightest.